Which of your patients could benefit from JYSELECA?

Patients with UC in the SELECTION study had varying  levels of treatment experience

Biologic-Naïve patients in the SELECTION clinical trial (n = 659)1

Concomitant medications at baseline



Reference: 1. Feagan BG, Danese S, Loftus EV Jr, et al. Lancet 2021;397:2372–2384. 

INDICATIONS: JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

GB-IBD-FIL-202209-00005 | Date of preparation February 2023

Adverse events should be reported.

For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.

Adverse events should be reported.

For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.

Adverse events should be reported.

For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.